Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Keynote Fireside Chat
How do you balance your BD strategy while also remaining poised for unanticipated opportunity?
Listen in as veteran biotech leader Jim Mullen shares insight from his considerable experience in the industry and hear about his new company's focus: helping small biotech do development in Europe
Explore the current trends in alternative financing for different stages of biotech investment, and the implications for future financing and development strategy
Here the story behind the story from Axial CEO David Donabedian, on this 2017 Fierce 15 biotech company, including key takeaways on lessons learned
What are the latest trends in raising capital and how are they impacting biotech investment in the US? How can choosing your partners impact your success?
Hear from this 2017 Fierce 15 biotech winner's Chief Business Officer on a busy year and gain insight from an inside look at recent key development deals helping to shape the future.
What, when, and where, matters in partnering strategy between small biotech and pharma, discuss the different elements that need to be considered when laying out your long term commercial strategy.
What makes a deal creative ? How does necessity lead to invention when thinking outside the box on partnerships, licensing, collaboration and other business development deals in biotech and pharma?
How important is an understanding of the commercial environment to a successful transaction? What are the risks of not aligning with partners on market potential and commercial requirements?
How might future and emerging tech modalities impact biotech deal-making?
A new twist on future predictions in deal making- including a closer look at disruptive technology and the impact of data on business development deals in biopharma